<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01890538</url>
  </required_header>
  <id_info>
    <org_study_id>KOU KAEK 2013/174</org_study_id>
    <nct_id>NCT01890538</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo</brief_title>
  <official_title>Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo: A Double Blind Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kocaeli University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kocaeli University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate efficacy of two different intravenous drugs (dimenhydrinate
      and piracetam) in the symptomatic management of peripheral vertigo.

      The patients will be randomized in two groups according to symptomatic treatment modalities:
      Dimenhydrinate (100 mg) and piracetam (2 g) will be given in 100 cc normal saline in 30
      minutes. Each patient will be asked if her/his vertigo symptoms resolved or not, according to
      a numeric rating scale (0=no vertigo, 10=worst possible vertigo). The patient will be rate
      the intensity of symptoms in the following times:

        -  Numeric rating scale (1 to 10): Admission

        -  Numeric rating scale (1 to 10): After the study drug (No ambulation)*

        -  Numeric rating scale (1 to 10): After the study drug (Ambulation)*

             -  Ambulation refers to head movements or walking in the room, if applicable.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in numeric rating scale</measure>
    <time_frame>Change from baseline in numeric rating scale at 30th minute</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Peripheral Vertigo</condition>
  <arm_group>
    <arm_group_label>Piracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 g intravenous piracetam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dimenhydrinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dimenhydrinate 100 mg intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of 100 mg dimenhydrinate intravenous</intervention_name>
    <arm_group_label>Dimenhydrinate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 g piracetam intravenous</intervention_name>
    <arm_group_label>Piracetam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presenting to emergency department with vertigo symptoms

          -  Adult patients (over 18)

          -  Agree to participate to study (understanding the study protocol and signing the
             informed consent form)

        Exclusion Criteria:

          -  Patients under 18 years

          -  Patients diagnosed with ischemic/hemorrhagic stroke after neuroimaging

          -  Patient diagnosed with transient ischemic attack

          -  Pregnants

          -  Patients taking any analgesics or antihistaminic drugs last 24 hours

          -  Documented or declared allergy to dimenhydrinate, piracetam or benzodiazepines

          -  Patients who do not agree to participate to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nurettin Özgür Doğan, M.D., Assistant Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kocaeli University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kocaeli University</name>
      <address>
        <city>Kocaeli</city>
        <zip>41000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=11020677</url>
  </link>
  <reference>
    <citation>Scholtz AW, Schwarz M, Baumann W, Kleinfeldt D, Scholtz HJ. Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallel-group clinical study. Clin Ther. 2004 Jun;26(6):866-77.</citation>
    <PMID>15262457</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2013</study_first_submitted>
  <study_first_submitted_qc>June 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2013</study_first_posted>
  <last_update_submitted>May 2, 2014</last_update_submitted>
  <last_update_submitted_qc>May 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kocaeli University</investigator_affiliation>
    <investigator_full_name>Nurettin Özgür Doğan</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>vertigo</keyword>
  <keyword>dimenhydrinate</keyword>
  <keyword>piracetam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vertigo</mesh_term>
    <mesh_term>Dizziness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimenhydrinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

